Cite
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.
MLA
Platt, Adam, et al. “A Retrospective Analysis of RET Translocation, Gene Copy Number Gain and Expression in NSCLC Patients Treated with Vandetanib in Four Randomized Phase III Studies.” BMC Cancer, vol. 15, no. 1, Apr. 2015, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-015-1146-8.
APA
Platt, A., Morten, J., Qunsheng Ji, Elvin, P., Womack, C., Xinying Su, Donald, E., Gray, N., Read, J., Bigley, G., Blockley, L., Cresswell, C., Dale, A., Davies, A., Tianwei Zhang, Shuqiong Fan, Haihua Fu, Gladwin, A., Harrod, G., & Stevens, J. (2015). A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer, 15(1), 1–10. https://doi.org/10.1186/s12885-015-1146-8
Chicago
Platt, Adam, John Morten, Qunsheng Ji, Paul Elvin, Chris Womack, Xinying Su, Emma Donald, et al. 2015. “A Retrospective Analysis of RET Translocation, Gene Copy Number Gain and Expression in NSCLC Patients Treated with Vandetanib in Four Randomized Phase III Studies.” BMC Cancer 15 (1): 1–10. doi:10.1186/s12885-015-1146-8.